

Paul Nioi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4695981/publications.pdf>

Version: 2024-02-01

8
papers

415
citations

1307594

7
h-index

1588992

8
g-index

12
all docs

12
docs citations

12
times ranked

1063
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene-level analysis of rare variants in 379,066 whole exome sequences identifies an association of GIGYF1 loss of function with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 21565.	3.3	25
2	Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence. <i>Toxicological Sciences</i> , 2019, 167, 593-603.	3.1	17
3	Comment on "Using Human "Experiments of Nature"™ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors"; <i>Drug Safety</i> , 2018, 41, 1097-1099.	3.2	1
4	Combining hiPSCs and Human Genetics: Major Applications in Drug Development. <i>Cell Stem Cell</i> , 2017, 21, 161-165.	11.1	12
5	Variant <i>ASGR1</i> Associated with a Reduced Risk of Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2131-2141.	27.0	137
6	Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. <i>Bone</i> , 2016, 84, 148-159.	2.9	86
7	Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1457-1467.	2.8	63
8	Utilization of Human Nuclear Receptors as an Early Counter Screen for Off-Target Activity: A Case Study with a Compendium of 615 Known Drugs. <i>Toxicological Sciences</i> , 2015, 145, 283-295.	3.1	10